22 May 2013
Keywords: amarin, acquires, usa, rights, permax, nasdaq-listed, finalized
Article | 15 July 2002
Nasdaq-listed Amarin has finalized its purchase of the remaining USrights to Parkinson's disease drug Permax (pergolide mesylate), the
company has ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
There are no related articles.
21 May 2013
© 2013 thepharmaletter.com